Vitamin D3 + K2New

Reviewed Sep 30, 2026

As of September 2026, the vitamin D3 + K2 pairing is backed by two of the most rigorous recent trials in the field. In the VITAL Telomere study — a sub-study of the 25,871-person VITamin D and OmegA-3 TriaL (VITAL) — 1,031 adults had leukocyte telomere length measured at baseline, year 2 and year 4. Compared with placebo, 2,000 IU/day of vitamin D3 significantly reduced telomere attrition by 0.14 kilobases (about 140 base pairs) over four years (p = 0.039), keeping telomeres roughly 0.035 kb/year longer than placebo (p = 0.037) — a difference the investigators described as comparable to about three years of cellular aging. Marine omega-3 (1 g/day) showed no significant effect on telomere length. Telomere shortening is a hallmark of biological aging, though it is one biomarker among many and these are findings from a single trial. Separately, the DO-HEALTH trial (777 older adults, DNA-methylation aging clocks over 3 years) found omega-3 modestly slowed several epigenetic-aging clocks, while vitamin D and exercise showed no significant individual effect and a small additive signal appeared when all three were combined.

The K2 (menaquinone-7) component addresses where calcium ends up. In the 2026 VitaK-CAC randomized trial, 180 patients with symptomatic coronary artery disease (baseline calcium score 50–400 Agatston units) received MK-7 360 µg/day or placebo for two years. Coronary artery calcium rose from a median 145 to 214 units on placebo versus 135 to 184 units on MK-7 — a statistically significant between-group difference (p = 0.02) driven by slower calcification of previously non-calcified plaque, with no significant adverse effects. This fits the long-standing rationale for pairing the two: vitamin D3 improves calcium absorption while K2 activates matrix GLA protein to help direct that calcium into bone rather than arterial walls. These are population-level results from specific study groups and do not guarantee individual outcomes. Vitamin D3 + K2 is a dietary supplement, not a drug, and is not intended to diagnose, treat, cure or prevent any disease. Because K2 can interact with warfarin and other vitamin-K-antagonist blood thinners, and because higher-dose vitamin D calls for monitoring blood calcium and 25(OH)D levels, discuss dosing with your physician.